CORDIAL progress presented at EuroPD 2025 in Valencia
The CORDIAL team joined EuroPD 2025 in Valencia, Spain (8–10 October 2025)—Europe’s leading meeting focused on peritoneal dialysis (PD) and home hemodialysis, hosted at the Palacio de Congresos Valencia.
At the conference, Karin Gerritsen (UMC Utrecht) and Sangita Swapnasrita presented new results from the CORDIAL project, which is developing and clinically validating next-generation, more sustainable dialysis technologies—including a portable PD system (WEAKID) that continuously regenerates dialysate using sorbents.
Invited talk: novel sorbents for home dialysis
Karin Gerritsen delivered an invited talk titled “Novel Sorbent Technologies in Home Dialysis” as part of Parallel Session 5: Technological Innovation in PD. Her presentation highlighted how sorbent-based approaches can help reduce the infrastructure burden of dialysis—particularly by enabling dialysate regeneration and supporting more flexible, home-based treatment pathways. Early clinical experience was presented with three regenerative dialysis systems based on modified REDY technology: the NeoKidney portable hemodialysis device (Nextkidney), the WEAKID continuous flow PD system from the CORDIAL project, as well as the VIVA Kompact (AWAK PD) rapid-cycling peritoneal dialysis regeneration platform. Future perspectives were discussed, including further miniaturization strategies, advanced membrane technologies, and the longer-term development of (partially) implantable dialysis solutions.
Accepted abstract: a computational model to accelerate SAPD optimization
Sangita Swapnasrita’s abstract was accepted at EuroPD 2025 and showcased a new computational model for Sorbent-assisted Peritoneal Dialysis (SAPD). The model represents rapid cycling of dialysate through a single-lumen PD catheter, combined with continuous dialysate regeneration via a sorbent unit and a dialysate reservoir—mirroring the core operating principle behind WEAKID/SAPD systems.
In the presented work, the model was validated against both preclinical pig data and clinical results from the CORDIAL trial, demonstrating a close match between predicted and measured solute concentrations across multiple compartments (including device in- and outflow lines and the dialysate reservoir).
After validation, the model can be used to virtually explore how key design and treatment parameters—such as sorbent mass, flow rates, tidal volume, recirculation fraction, reservoir volume, and peritoneal membrane characteristics—influence ultrafiltration and solute clearance, supporting faster iteration on device settings and personalization strategies.
Why this matters: by enabling robust “in-silico” evaluation of SAPD configurations, the approach can reduce the need for unnecessary testing in animals and humans, while accelerating optimization toward safe and effective home-based systems.